April 25, 2017 / 6:01 AM / 4 months ago

BRIEF-Servier,CTI Biopharma expand Pixuvri license and collaboration agreement

April 25 (Reuters) - Cti Biopharma Corp

* Servier and CTI Biopharma expand license and collaboration agreement to develop and commercialize Pixuvri

* Says Servier will commercialize Pixuvri in all markets except US

* Says CTI Biopharma will retain rights to commercialize Pixuvri in US

* CTI Biopharma - Servier to pay CO EUR 12 million with potential for CO to receive EUR 76 million in additional sales and regulatory milestone payments

* CTI Biopharma - as specific post-authorization requirement, Pixuvri is currently being investigated in a phase iii clinical trial, pix306

* CTI Biopharma - Pixuvri granted conditional marketing authorization from European Commission Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below